These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35160092)

  • 1. Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease.
    Orfanoudaki E; Zacharopoulou E; Kitsou V; Karmiris K; Theodoropoulou A; Mantzaris GJ; Tzouvala M; Michopoulos S; Zampeli E; Michalopoulos G; Karatzas P; Viazis N; Liatsos C; Bamias G; Koutroubakis IE; On Behalf Of The Hellenic Group For The Study Of Ibd
    J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
    Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
    Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey.
    Ellul P; Revés J; Abreu B; Chaparro M; Gisbert JP; Allocca M; Fiorino G; Barberio B; Zingone F; Pisani A; Cassar D; Michalopoulos G; Mantzaris G; Koutroubakis I; Karmiris K; Katsanos K; Ďuricova D; Burisch J; Madsen GR; Maaser C; Naila A; Orfanoudaki E; Milivojevic V; Buisson A; Avedano L; Leone S; Torres J
    J Crohns Colitis; 2022 Aug; 16(7):1070-1078. PubMed ID: 35037033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2-inactivated vaccine hesitancy and the safety in inflammatory bowel disease patients: a single-center study.
    Cao Y; Feng J; Duan S; Yang Y; Zhang Y
    Therap Adv Gastroenterol; 2022; 15():17562848221101722. PubMed ID: 35706827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study.
    Shehab M; Zurba Y; Al Abdulsalam A; Alfadhli A; Elouali S
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study.
    Shehab M; Alrashed F; Abdullah I; Alfadhli A; Ali H; Abu-Farha M; Channanath AM; Abubaker JA; Al-Mulla F
    Front Med (Lausanne); 2022; 9():881027. PubMed ID: 35755075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Vaccination Among Individuals With Inflammatory Bowel Disease: Perception, Efficacy, and Safety.
    Weaver KN; Kappelman MD; Long MD
    Gastroenterol Hepatol (N Y); 2022 Jul; 18(7):388-399. PubMed ID: 36397773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning.
    Jarynowski A; Semenov A; Kamiński M; Belik V
    J Med Internet Res; 2021 Nov; 23(11):e30529. PubMed ID: 34662291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease.
    Elkharsawi A; Arnim UV; Schmelz R; Sander C; Stallmach A; Teich N; Walldorf J; Reuken PA
    Z Gastroenterol; 2022 Jan; 60(1):77-80. PubMed ID: 35042256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.
    Ou MT; Boyarsky BJ; Motter JD; Greenberg RS; Teles AT; Ruddy JA; Krach MR; Jain VS; Werbel WA; Avery RK; Massie AB; Segev DL; Garonzik-Wang JM
    Transplantation; 2021 Oct; 105(10):2170-2174. PubMed ID: 33859151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007744. PubMed ID: 25340915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations.
    Murthy SK; Kuenzig ME; Windsor JW; Ghia JE; Griffiths AM; Panaccione R; Seow CH; Benchimol EI; Bernstein CN; Bitton A; Huang JG; Jones JL; Lee K; Kaplan GG; Mukhtar MS; Tandon P; Targownik LE; Gibson DL
    J Can Assoc Gastroenterol; 2021 Dec; 4(Suppl 2):S54-S60. PubMed ID: 34755040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.
    Khan N; Mahmud N
    Gastroenterology; 2021 Sep; 161(3):827-836. PubMed ID: 34048782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host factors and history of SARS-CoV-2 infection impact the reactogenicity of BNT162b2 mRNA vaccine: results from a cross-sectional survey on 7,014 workers in healthcare.
    Ughi N; Del Gaudio F; Dicuonzo A; Orso M; Micheloni G; Puoti M; Pani A; Scaglione F; Zoppini L; Rossetti C; Epis OM; Bellavia G; Giroldi S; Moreno M; Bosio M
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7985-7996. PubMed ID: 34982462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey.
    Tsai R; Hervey J; Hoffman K; Wood J; Johnson J; Deighton D; Clermont D; Loew B; Goldberg SL
    JMIR Public Health Surveill; 2022 Jan; 8(1):e29872. PubMed ID: 34709184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies.
    Shehab M; Alrashed F; Alfadhli A; Alotaibi K; Alsahli A; Mohammad H; Cherian P; Al-Khairi I; Alphonse Thanaraj T; Channanath A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960217
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 Vaccination in Inflammatory Bowel Disease (IBD).
    Kubas A; Malecka-Wojciesko E
    J Clin Med; 2022 May; 11(9):. PubMed ID: 35566802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Immunizations for the Adult Patient With Inflammatory Bowel Disease-A Systematic Review and Meta-analysis.
    Desalermos A; Pimienta M; Kalligeros M; Shehadeh F; Diamantopoulos L; Karamanolis G; Caldera F; Farraye FA
    Inflamm Bowel Dis; 2022 Sep; 28(9):1430-1442. PubMed ID: 34849941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The COVID-19 Vaccination Hesitancy Among the People With Inflammatory Bowel Disease in China: A Questionnaire Study.
    Wu X; Lin J; Buch H; Ding Q; Zhang F; Cui B; Ji G
    Front Public Health; 2021; 9():731578. PubMed ID: 34708016
    [No Abstract]   [Full Text] [Related]  

  • 20. SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
    Prentice RE; Rentsch C; Al-Ani AH; Zhang E; Johnson D; Halliday J; Bryant R; Begun J; Ward MG; Lewindon PJ; Connor SJ; Ghaly S; Christensen B
    GastroHep; 2021 Jul; 3(4):212-228. PubMed ID: 34539248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.